Abstract
Actually gemcitabine is a main drug in the treatment of non small cell lung cancer (NSCLC). The doublet gemcitabine and cisplatin is a standard treatment, widely used in the world. The review of the literature, and specially several recent randomised phase III trial in stage IV NSCLC demonstrates the reproducibility of the results, and a manageable toxicity which allows its use in preoperative setting in stages I, II and resectable III. The carboplatin-gemcitabine doublet is under investigation.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carboplatin / administration & dosage
-
Carboplatin / adverse effects
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / surgery
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Clinical Trials, Phase III as Topic
-
Combined Modality Therapy
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives*
-
Docetaxel
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Gastrointestinal Diseases / chemically induced
-
Gemcitabine
-
Hematologic Diseases / chemically induced
-
Humans
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / surgery*
-
Neoadjuvant Therapy
-
Paclitaxel / administration & dosage
-
Paclitaxel / adverse effects
-
Paclitaxel / analogs & derivatives*
-
Pneumonectomy
-
Randomized Controlled Trials as Topic
-
Remission Induction
-
Reproducibility of Results
-
Taxoids*
-
Treatment Outcome
-
Vinblastine / administration & dosage
-
Vinblastine / adverse effects
-
Vinblastine / analogs & derivatives*
-
Vinorelbine
Substances
-
Taxoids
-
Deoxycytidine
-
Docetaxel
-
Vinblastine
-
Etoposide
-
Carboplatin
-
Paclitaxel
-
Cisplatin
-
Vinorelbine
-
Gemcitabine